Delivery Order SPE2DB20D3101-SPE2DB25FRUG0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,124.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed price contract was awarded competitively with no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,519.77 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. Performance will be executed from the company's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Naloxone HCL 4 mg nasal spray (two-dose unit) valued at $1,397.76. The contract utilizes firm fixed pricing with a completion date of September 15, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-pack units) on July 28, 2025, with completion scheduled for July 29, 2025. This non-set-aside, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $8,603.40 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray on July 23, 2025, with completion targeted for July 24, 2025. This non-set-aside, firm fixed-price contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999.999 billion vehicle running through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.40 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside contract is classified as a child award, indicating it derives from a larger contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,301.63 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray (2-pack units) on July 23, 2025, with completion required by July 24, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,507.14 for Naloxone HCL 4 mg nasal spray on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete in open federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,580.96 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that supplies...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,588.95 to AmerisourceBergen Drug Corp for the supply of Naloxone 4mg nasal spray (2-pack units) on September 18, 2025, with an ultimate completion date of October 16, 2025. This firm fixed-price, non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999 global pharmaceutical support vehicle...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUG0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,572.48 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and running through December 2026. The product will be supplied from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order supports the Defense Logistics Agency's Medical Supply Chain mission to furnish pharmaceutical products and medical supplies to military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a substantial federal contract portfolio with DLA that encompasses a comprehensive range of medications and medical supplies across multiple therapeutic domains. The Pharmaceutical Prime Vendor Global Program vehicle under which this order falls enables flexible procurement of critical medical commodities, including specialty medications, brand-name and generic drugs, and related healthcare supplies to support defense health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 9/3/25 |